Humoral and cell-mediated immune responses in humans to the A/California/07/2009 (H1N1) virus, A(H1N1)pdm2009

Voprosy Virusologii

Volumn 58, Issue 2, 2013, Pages 38-42

  Naikin, A N ^a   Donina, S A ^a   Petuhova, G D ^a   Korenkov, D A ^a   Doroshenko, E M ^a   Grigorieva, E P ^a   Suvorova, M A ^a   Rudenko, L G ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Russian Federation)

Author keywords

Anti influenza immunity; Cell mediated immune response; Immunity to influenza A strains

Indexed keywords

ORTHOMYXOVIRIDAE;

VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; CROSS REACTION; FEMALE; GENETICS; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; MALE; MIDDLE AGED; PANDEMIC; PRESCHOOL CHILD; RUSSIAN FEDERATION; T LYMPHOCYTE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; CROSS REACTIONS; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PANDEMICS; RUSSIA; T-LYMPHOCYTES;

EID: 84880047545     PISSN: 05074088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Baker M. G., Wilson N., Huang Q. S. et al. Pandemic influenza A (H1N1) in New Zealand: the experience from April to August 2009. Euro Surveill. 2009: ii; 19319.
2. Center for Disease Control and Prevention. Serum cross-reactive antibody response to a novel influenza A (H 1N1) virus after vaccination with reasonal influenza vaccine.//MMWR. 2009;58:521-24. http://www.cdc.gov/mmwr/preview/ mmwrhtml/mm5819al.htm.
3. Coligan J. E. et al., eds. Current protocols in Immunology. Wiley press; 2004.
4. Original antigenic sin and pandemic (H1N1) 2009. Emerg. Infect. Dis. 2010;16(6):1028-29.
5. Garten R. J., Davis C. T., Russell C. A. et al. Antigenic and genetic characteristics of swine-origin 2009 (H1N1) influenza viruses circulating in human. Science. 2009;325:197-201.
6. Grebe K. M., Yewdell J. W., Bennink J. R. Heterosubtypic immunity to influenza A virus: where do we stand? Microb. Infect. 2008;10:1024-29.
7. Hancock K., Veguilla V., Lu X. et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 2009;361:1945-52.
8. He X. S., Holmes T. H., Zhang C. et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccine. J. Virol. 2006;80(23):11756-6.
9. Kelly H., Grant K. Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill. 2009;14:ii; 19288.
10. Maritz J., Maree L., Preiser W. Pandemic influenza A (H1N1) 2009:the experience of the first six manth. Clin. Chem. Lab. Med. 2010;48:11-21.
11. Medina R. A., Manicassamy B. Stertz S., et al. Pandemic 2009 H1N1 vaccine protect against 1918 Spanish influenza virus. Nat. Commun. 2010;1-6./1:28/DOI: 10.1038/ncomms1026/www.nature.cjm/naturecommunications
12. Skowronski DM., Hollers T. S., Janjua NZ et al. Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic. Can. Med. Assoe. J. 2010;182:1851-6.
13. Skowronski DM., Hollers T. S., McElhaney J. E. et al. Immunoepidemiologic correlatates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age. J. Infect. Dis. 2011;203(2):158-67.
14. Tsai T. F., Pedotti P., Hilbert A. et al. Regional and age-specific patterns of pandemic H1N1 influenza virus seroprevalence inferred from vaccine clinical trials, August-October 2009. Euro Surveill. 2010;15:ii: 19624.
15. Waaln K., Kilander A., Dudman S. G. et al. High prevalence of antibodies to the 2009 pandemic influenza A (HIN1) virus in the Norwegian population following a major epidemic and large vaccination compaing in autumn 2009. Euro Surveill. 2010;-15; N 31. ii:19633.
16. Wold Health Organization. Transcript of statement by Margaret Chan, Director-General of Wold Health Organization, 11 June 2009. http://www.who.int/ media-centre/influenza A (H1N1) presstranscript.-20090611.pdf.
17. Wold Health Organization. Weekly Epidemiol, rec. 2009;84(21):185-96.
18. Wold Health Organization. Influenza A (H1N1) - update 52. 22 June 2009 07:00GMT.
19. Wold Health Organization. Weekly Epidemiol, rec. 2009;85(24):229-36.
20. Wold Health Organization. Characteristics of the emergent influenza A (H1N1) viruses and recommendations for vaccine development. 26 May 2009.
21. Wrammert J., Koutsonanos D., Li G Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 2011; DOI:10.1084/jem, 20101352.
22. Writing Committee of the WHO consultation on clinical aspects of pandemic (H1N1) 2009 influenza. Clinical aspects of pandemic 2009 influenza A (H 1N1) virus infection. N. Engl. J. Med. 2010;362:1708-19.